Key Takeaways:
RemeGen Co. (09995.HK) received a $650 million upfront payment from global biopharmaceutical firm AbbVie Inc. for an exclusive licensing agreement for its novel cancer drug, RC148.
"The collaboration between the two parties is currently progressing smoothly," RemeGen said in a statement to the Hong Kong Stock Exchange.
The payment is part of a strategic partnership focused on the development and commercialization of RC148, a PD-1/VEGF bispecific antibody. Shares of RemeGen surged as much as 9.1% to HK$118.80 on the news. The deal provides AbbVie with an exclusive license to the drug outside of the greater China region.
The substantial upfront payment significantly strengthens RemeGen's financial position and de-risks its development pipeline. For AbbVie, the deal marks a strategic investment to expand its oncology portfolio with a promising bispecific antibody asset.
RC148 is designed to simultaneously target the programmed death-ligand 1 (PD-1) and vascular endothelial growth factor (VEGF) pathways, two key targets in cancer therapy. This dual-targeting mechanism has shown potential in treating a variety of solid tumors in early-stage trials.
The collaboration's success will depend on upcoming clinical trial results and regulatory approvals. Investors will be closely watching for data from Phase 2 and Phase 3 studies to assess the drug's efficacy and safety profile against existing cancer treatments.
The $650 million payment validates RemeGen's internal research capabilities and provides substantial non-dilutive capital to advance its broader pipeline. The next major catalyst for the partnership will be the initiation of global Phase 2 trials for RC148, expected within the next 12 to 18 months.
This article is for informational purposes only and does not constitute investment advice.
